

Electronic Supplementary Information

Catalytic Enantioselective Addition of Terminal 1,3-Diynes to N-Sulfonyl Aldimines: Access to Chiral Diynylated Carbinamines

Tian-Lin Liu,^a Heng-Xia Zhang,^a Yan Zheng,^a Qingwei Yao,^b Jun-An Ma*^a

^a Department of Chemistry, Tianjin University, Tianjin 300072, P. R. of China,

Fax: (+86)-22-2740-3475; E-mail: majun_an68@tju.edu.cn

^b Sphinx Scientific Laboratory Corporation, Sycamore, IL 60178, USA

Contents

1. General information	S2
2. General procedure for the enantioselective diynylation	S3
3. Analytical data for the addition adducts	S3
4. Further transformation of adduct 3aa	S20
5. References	S23
6. NMR Spectra and HPLC Charts for the Addition Adducts	S24
7. X-ray Analysis for the adduct 3ad	S93


1. General information:

^1H , ^{13}C and ^{19}F were recorded on Varian Mercury Plus 400 instruments or Bruker AV 400 MHz at 400 MHz (^1H NMR), 100 MHz (^{13}C NMR), as well as 376 MHz (^{19}F NMR). Chemical shifts were reported in ppm from the solvent resonance as the internal Me_4Si or CDCl_3 . LRMS were recorded on a VGZAB-HS spectrometer with the ESI resource. HRMS were recorded on an IonSpec Bruker Daltonics, Inc. APEXIII 7.0 TESLA FTMS mass spectrometer with ESI resource or a miorOTOF-QII mass spectrometer with APCI resource. Optical rotations were determined using an Autopol IV-T. IR spectra were recorded on an AVATAR 360 FT-IR spectrometer. Melting points were measured on a WRS-1A digital melting point apparatus and are uncorrected. HPLC analyses were carried out on a Hewlett Packard Model HP 1200 instrument. X-ray structural analyses was conducted on the XtaLAB mini (600 W, SHINE, CCD, 75mm, 0.1 electrons/pixel/sec).


Materials:

Diethyl ether and toluene were distilled from sodium / benzophenone prior to use; CH_2Cl_2 (DCM) and $\text{ClCH}_2\text{CH}_2\text{Cl}$ (DCE) were distilled from CaH_2 . All purchased reagents were used without further purification. Analytical thin layer chromatography was performed on 0.20 mm Qingdao Haiyang silica gel plates. Silica gel (200-300 mesh) (from Qingdao Haiyang Chem. Company, Ltd.) was used for flash chromatography. 3,3-disubstituted (S)-binol-derived Ligands **L2–L10** were synthesized by the known method.¹ Substituted terminal 1,3-Diynes and Substituted *N*-sulfonyl aldimines were synthesized according to the literature.² Dimethylzinc (1.2M solution in toluene) were purchased from ACROS Organics. Standard reagents and solvents were purified according to known procedures.

666, 574, 545 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 6.8 min, t_R (major) = 12.3 min.




***N*-(1-(4-fluorophenyl)-5-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ba)** : 35.9 mg, 89% yield, 97% ee; mp 130–133 °C; $[\alpha]_D^{20}$ +96.1 (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.79 (d, J = 8.2 Hz, 2H), 7.44 (t, J = 7.2 Hz, 4H), 7.38 (d, J = 7.1 Hz, 1H), 7.33 (t, J = 7.2 Hz, 4H), 7.00 (t, J = 8.6 Hz, 2H), 5.43 (d, J = 9.1 Hz, 1H), 5.25 (d, J = 9.1 Hz, 1H), 2.39 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 162.8 (d, $^1J_{\text{F-C}}$ = 246.5 Hz), 144.0, 136.9, 132.6, 132.5 (d, $^4J_{\text{F-C}}$ = 3.1 Hz), 129.7, 129.6, 129.2 (d, $^3J_{\text{F-C}}$ = 8.4 Hz), 128.5, 127.5, 121.1, 115.7 (d, $^2J_{\text{F-C}}$ = 21.7 Hz), 79.2, 78.2, 72.8, 71.5, 49.3, 21.6; ^{19}F -NMR (376 MHz, CDCl_3) δ -112.89 – -112.97 (m, 1F); MS (ESI) found: 426.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{FNNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 426.0940, found: 426.0937; IR (neat) ν 3447, 3252, 3049, 2955, 2904, 2853, 2245, 1601, 1506, 1435, 1332, 1157, 1090, 1039, 778, 668, 577, 540 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 80 / 20, 1.0 mL / min, 220 nm) t_R (major) = 4.3 min, t_R (minor) = 4.7 min.




***N*-(1-(4-chlorophenyl)-5-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ca)** : 39.0 mg, 93% yield, 91% ee; mp 138–140 °C; $[\alpha]_D^{20}$ +84.8 (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.78 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 7.0 Hz, 2H), 7.42 – 7.37 (m, 3H), 7.36 – 7.27 (m, 6H), 5.43 (d, J = 9.0 Hz, 1H), 5.02 (d, J = 9.1 Hz, 1H), 2.40 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 144.1, 136.8, 135.1, 134.7, 132.6, 129.7, 129.6, 129.0, 128.7, 128.5, 127.5, 121.0, 79.3, 77.8, 72.6, 71.6, 49.4, 21.6; MS (ESI)

found: 422.1 $[M+Na]^+$; HR-MS (ESI) calcd for $C_{24}H_{18}ClNNaO_2S$ $[M+Na]^+$ 442.0644, found: 442.0640; IR (neat) ν 3426, 3250, 3050, 2923, 2856, 2245, 1579, 1490, 1334, 1157, 1091, 1015, 814, 757, 666, 573 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 8.5 min, t_R (major) = 22.0 min.




***N*-(1-(4-bromophenyl)-5-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3da)** : 42.3 mg, 91% yield, 98% ee; mp 124–126 °C; $[\alpha]_D^{20}$ +5.2 (*c* 1.0, CH_2Cl_2); 1H -NMR ($CDCl_3$, 400 MHz) δ 7.77 (d, *J* = 8.1 Hz, 2H), 7.45 (d, *J* = 8.1 Hz, 4H), 7.38 (d, *J* = 7.2 Hz, 1H), 7.36 – 7.30 (m, 6H), 5.40 (d, *J* = 9.1 Hz, 1H), 5.12 (d, *J* = 9.1 Hz, 1H), 2.40 (s, 3H); ^{13}C -NMR ($CDCl_3$, 100 MHz) δ 144.1, 136.8, 135.7, 132.6, 131.9, 129.7, 129.6, 129.0, 128.5, 127.5, 122.9, 121.0, 79.3, 77.8, 72.7, 71.6, 49.5, 21.6; MS (ESI) found: 486.0 $[M+Na]^+$; HR-MS (ESI) calcd for $C_{24}H_{18}BrNNaO_2S$ $[M+Na]^+$ 486.0139, found: 486.0148; IR (neat) ν 3427, 3264, 3051, 2922, 2855, 2244, 1579, 1486, 1434, 1333, 1159, 1092, 813, 667, 571, 546 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 9.2 min, t_R (major) = 24.1 min.




***N*-(5-phenyl-1-(p-tolyl)penta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ea)** : 37.1 mg, 93% yield, 98% ee; mp 148–150 °C; $[\alpha]_D^{20}$ +50.4 (*c* 1.0, CH_2Cl_2); 1H -NMR ($CDCl_3$, 400 MHz) δ 7.80 (d, *J* = 8.1 Hz, 2H), 7.45 (d, *J* = 7.1 Hz, 2H), 7.37 (d, *J* = 7.1 Hz, 1H), 7.35 – 7.30 (m, 6H), 7.14 (d, *J* = 7.8 Hz, 2H), 5.41 (d, *J* = 8.9 Hz, 1H), 4.89 (d, *J* = 9.0 Hz, 1H), 2.39 (s, 3H), 2.33 (s, 3H); ^{13}C -NMR ($CDCl_3$, 100 MHz) δ 143.9, 138.7, 137.0, 133.6, 132.5, 129.7, 129.5, 129.5, 128.5, 127.6, 127.2, 121.2,

78.9, 78.7, 73.0, 71.1, 49.7, 21.6, 21.1; MS (ESI) found: 422.1 $[M+Na]^+$; HR-MS (ESI) calcd for $C_{25}H_{21}NNaO_2S$ $[M+Na]^+$ 422.1191, found: 422.1183; IR (neat) ν 3443, 3251, 3026, 2921, 2857, 2244, 1596, 1432, 1331, 1156, 1089, 813, 758, 691, 668, 577 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) t_R (minor) = 8.6 min, t_R (major) = 15.7 min.




***N*-(1-(4-methoxyphenyl)-5-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3fa)** : 37.4 mg, 90% yield, 96% ee; mp 159–160 °C; $[\alpha]_D^{20} +70.4$ (c 1.0, CH_2Cl_2); 1H -NMR ($CDCl_3$, 400 MHz) δ 7.80 (d, J = 8.2 Hz, 2H), 7.45 (d, J = 6.9 Hz, 2H), 7.39 – 7.30 (m, 7H), 6.85 (d, J = 8.6 Hz, 2H), 5.40 (d, J = 8.8 Hz, 1H), 5.00 (d, J = 8.7 Hz, 1H), 3.79 (s, 3H), 2.39 (s, 3H); ^{13}C -NMR ($CDCl_3$, 100 MHz) δ 159.9, 143.8, 137.1, 132.5, 129.7, 129.5, 128.6, 128.6, 128.5, 127.5, 121.2, 114.2, 78.9, 78.8, 73.0, 71.1, 55.4, 49.5, 21.6; MS (ESI) found: 438.1 $[M+Na]^+$; HR-MS (ESI) calcd for $C_{25}H_{21}NNaO_3S$ $[M+Na]^+$ 438.1140, found: 438.1140; IR (neat) ν 3427, 3261, 3046, 2958, 2927, 2841, 2243, 1607, 1511, 1332, 1158, 1028, 817, 667, 573, 545 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.8 mL / min, 220 nm) t_R (minor) = 14.9 min, t_R (major) = 27.6 min.




***N*-(1-(3-methoxyphenyl)-5-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3ga)** : 38.6 mg, 93% yield, 94% ee; mp 132–135 °C; $[\alpha]_D^{20} +86.0$ (c 1.0, CH_2Cl_2); 1H -NMR ($CDCl_3$, 400 MHz) δ 7.80 (d, J = 8.1 Hz, 2H), 7.45 (d, J = 7.0 Hz, 2H), 7.37 (d, J = 7.1 Hz, 1H), 7.33 (d, J = 6.9 Hz, 4H), 7.28 – 7.24 (m, 1H), 7.04 (d, J = 7.6 Hz, 1H), 6.97 (s, 1H), 6.84 (dd, J = 8.2, 1.7 Hz, 1H), 5.42 (d, J = 9.0 Hz, 1H), 4.98 (d, J =

9.0 Hz, 1H), 3.78 (s, 3H), 2.39 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 159.9, 143.9, 138.0, 137.0, 132.5, 129.9, 129.7, 129.5, 128.5, 127.5, 121.2, 119.5, 114.5, 112.7, 79.0, 78.4, 72.9, 71.2, 55.3, 49.9, 21.6; MS (ESI) found: 438.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{25}\text{H}_{21}\text{NNaO}_3\text{S}$ $[\text{M}+\text{Na}]^+$ 438.1140, found: 438.1133; IR (neat) ν 3470, 3254, 3055, 2967, 2941, 2839, 2243, 1605, 1488, 1443, 1329, 1156, 1037, 755, 693, 668, 566, 545 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) t_{R} (minor) = 10.2 min, t_{R} (major) = 21.7 min.




***N*-(1-(2-chlorophenyl)-5-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3ha)**: 38.2 mg, 91% yield, 94% ee; mp 167–168 °C; $[\alpha]_{\text{D}}^{20}$ +31.4 (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.76 (d, J = 8.0 Hz, 2H), 7.52 – 7.46 (m, 1H), 7.43 (d, J = 7.2 Hz, 2H), 7.35 (d, J = 7.0 Hz, 1H), 7.33 – 7.24 (m, 5H), 7.23 – 7.18 (m, 2H), 5.75 (d, J = 8.6 Hz, 1H), 5.47 (d, J = 8.6 Hz, 1H), 2.35 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 143.8, 136.9, 134.3, 132.9, 132.6, 130.1, 130.1, 129.6, 129.5, 129.4, 128.5, 127.5, 127.4, 121.1, 79.2, 77.9, 73.0, 70.9, 47.9, 21.6; MS (ESI) found: 422.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{ClNNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 442.0644, found: 442.0642; IR (neat) ν 3426, 3260, 3058, 2919, 2836, 2242, 1426, 1330, 1157, 1028, 754, 668, 578, 548 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_{R} (major) = 8.8 min, t_{R} (minor) = 15.1 min.




***N*-(1-(2-bromophenyl)-5-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3ia)**: 42.2 mg, 90% yield, 95% ee; mp 145–147 °C; $[\alpha]_{\text{D}}^{20}$ +17.0 (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.77 (d, J = 8.2 Hz, 2H), 7.50 (d, J = 7.9 Hz, 2H), 7.44

(d, $J = 7.0$ Hz, 2H), 7.36 (d, $J = 7.1$ Hz, 1H), 7.34 – 7.26 (m, 5H), 7.15 (t, $J = 7.7$ Hz, 1H), 5.75 (d, $J = 8.3$ Hz, 1H), 5.37 (d, $J = 8.3$ Hz, 1H), 2.37 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 143.9, 136.8, 135.9, 133.5, 132.6, 130.3, 129.6, 129.5, 128.5, 128.0, 127.5, 122.9, 121.1, 79.2, 77.9, 73.0, 71.1, 50.2, 21.6; MS (ESI) found: 486.0 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{BrNNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 486.0139, found: 486.0148; IR (neat) ν 3431, 3260, 3059, 2921, 2836, 2242, 1426, 1330, 1157, 1028, 754, 668, 577, 549 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) t_R (minor) = 10.1 min, t_R (major) = 16.4 min.




***N*-(1-(2-allylphenyl)-5-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide**


(3ja) : 38.7 mg, 91% yield, 92% ee; mp 112–113 °C; $[\alpha]_D^{20} +19.6$ (c 1.0, CH_2Cl_2); ^1H -NMR (400 MHz, CDCl_3) δ 7.81 (d, $J = 7.8$ Hz, 2H), 7.52 (d, $J = 7.3$ Hz, 1H), 7.44 (d, $J = 7.0$ Hz, 2H), 7.38 – 7.25 (m, 6H), 7.21 (t, $J = 8.2$ Hz, 2H), 6.08 – 5.90 (m, 1H), 5.64 (d, $J = 8.3$ Hz, 1H), 5.22 – 4.95 (m, 3H), 3.64 (dd, $J = 16.1, 6.3$ Hz, 1H), 3.44 (dd, $J = 15.9, 3.9$ Hz, 1H), 2.28 (s, 3H); ^{13}C -NMR (100 MHz, CDCl_3) δ 143.9, 137.8, 137.0, 136.6, 134.7, 132.5, 130.7, 129.6, 129.5, 129.2, 128.5, 128.0, 127.6, 127.1, 121.3, 116.6, 79.0, 78.8, 73.1, 71.1, 47.2, 36.4, 21.6; HR-MS (APCI) calcd for $\text{C}_{27}\text{H}_{24}\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$ 426.1522, found: 426.1531; IR (neat) ν 3258, 3071, 3023, 2963, 2924, 2854, 2242, 1597, 1425, 1330, 1157, 1025, 755, 695, 669, 578 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 5.6 min, t_R (major) = 9.2 min.



***N*-[1-(3,4-Dichloro-phenyl)-5-phenyl-penta-2,4-diynyl]-4-methyl-benzenesulfonamide (3ka)** : 42.7 mg, 94% yield, 90% ee; mp 125–127 °C; $[\alpha]_D^{20} +80.6$ (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.75 (d, *J* = 8.1 Hz, 2H), 7.49 (s, 1H), 7.45 (d, *J* = 7.2 Hz, 2H), 7.38 – 7.29 (m, 7H), 5.45 (d, *J* = 9.1 Hz, 1H), 5.39 (d, *J* = 9.1 Hz, 1H), 2.39 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 144.2, 136.8, 136.6, 132.9, 132.9, 132.6, 130.7, 129.8, 129.7, 129.3, 128.6, 127.4, 126.7, 120.9, 79.6, 77.2, 72.6, 71.9, 49.0, 21.7; MS (ESI) found: 476.0 [M+Na]⁺; HR-MS (ESI) calcd for C₂₄H₁₇Cl₂NNaO₂S [M+Na]⁺ 476.0255, found: 476.0249; IR (neat) ν 3428, 3252, 3059, 2923, 2855, 2242, 1468, 1437, 1329, 1156, 1090, 1036, 815, 757, 695, 668, 562 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.8 mL / min, 220 nm) *t*_R (minor) = 13.0 min, *t*_R (major) = 41.0 min.




4-methyl-*N*-(5-phenyl-1-(2,4,6-trimethoxyphenyl)penta-2,4-diyn-1-yl)benzenesulfonamide (3la) : 44.2 mg, 93% yield, 91% ee; mp 125–127 °C; $[\alpha]_D^{20} +10.6$ (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.68 (d, *J* = 8.2 Hz, 2H), 7.40 (d, *J* = 6.9 Hz, 2H), 7.33 – 7.25 (m, 3H), 7.18 (d, *J* = 7.9 Hz, 2H), 6.14 – 5.87 (m, 4H), 3.77 (s, 6H), 3.74 (s, 3H), 2.33 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 161.6, 157.8, 143.2, 137.4, 132.4, 129.2, 129.1, 128.4, 127.2, 121.7, 106.2, 90.9, 80.6, 77.7, 73.8, 66.7, 56.0, 55.4, 40.5, 21.5; MS (ESI) found: 498.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₇H₂₅NNaO₅S [M+Na]⁺ 498.1351, found: 498.1347; IR (neat) ν 3358, 3312, 3005, 2938, 2842, 2235, 1593, 1338, 1166, 1123, 811, 757, 706, 644, 571, 545 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 50 / 50, 0.6 mL / min, 220 nm) *t*_R (minor) = 13.3 min, *t*_R (major) = 18.3 min.




***N*-(1-(naphthalen-2-yl)-5-phenylpenta-2,4-diyn-1-yl)-4-methylbenzene-**

sulfonamide (3ma) : 40.5 mg, 93% yield, 92% ee; mp 141–143 °C; $[\alpha]_D^{20}$ +64.4 (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.89 (s, 1H), 7.80 (d, *J* = 8.1 Hz, 5H), 7.54 – 7.46 (m, 5H), 7.38 (d, *J* = 7.1 Hz, 1H), 7.35 (d, *J* = 7.5 Hz, 2H), 7.29 – 7.26 (m, 2H), 5.62 (d, *J* = 9.0 Hz, 1H), 5.15 (s, 1H), 2.35 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 143.9, 137.0, 133.7, 133.21, 133.0, 132.6, 129.7, 129.6, 128.9, 128.5, 128.2, 127.7, 127.5, 126.7, 126.6, 126.4, 124.8, 121.2, 79.1, 78.5, 73.0, 71.5, 50.2, 21.6; MS (ESI) found: 458.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₈H₂₁NNaO₂S [M+Na]⁺ 458.1191, found: 458.1179; IR (neat) ν 3420, 3257, 3056, 2959, 2925, 2854, 2244, 1325, 1155, 816, 761, 669, 573 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) *t*_R (major) = 13.5 min, *t*_R (minor) = 24.4 min.




***N*-(1-(furan-2-yl)-5-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide**

(3na) : 33.8 mg, 90% yield, 96% ee; mp 143–145 °C; $[\alpha]_D^{20}$ +78.6 (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.78 (d, *J* = 6.7 Hz, 2H), 7.44 (d, *J* = 7.5 Hz, 2H), 7.39 – 7.28 (m, 6H), 6.31 (d, *J* = 28.1 Hz, 2H), 5.51 (d, *J* = 8.7 Hz, 1H), 5.26 (d, *J* = 8.7 Hz, 1H), 2.38 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 148.5, 143.9, 143.4, 137.0, 132.6, 129.7, 129.6, 128.5, 127.4, 121.0, 110.6, 108.7, 79.1, 76.4, 72.8, 70.1, 44.2, 21.6; MS (ESI) found: 398.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₂H₁₇NNaO₃S [M+Na]⁺ 398.0827, found: 398.0828; IR (neat) ν 3434, 3250, 3073, 2923, 2856, 2242, 1436, 1336, 1161, 1029, 917, 813, 757, 673, 544 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) *t*_R (minor) = 7.9 min, *t*_R (major) = 17.0 min.




(E)-N-(1,7-diphenylhepta-1-en-4,6-diyn-3-yl)-4-methylbenzenesulfonamide (3oa) :

39.1 mg, 95% yield, 91% ee; mp 117–119 °C; $[\alpha]_D^{20} +58.6$ (c 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.83 (d, *J* = 8.2 Hz, 2H), 7.47 (d, *J* = 6.9 Hz, 2H), 7.40 – 7.26 (m, 10H), 6.75 (d, *J* = 15.8 Hz, 1H), 6.08 (dd, *J* = 15.8, 5.4 Hz, 1H), 5.06 (m, 1H), 4.91 (d, *J* = 9.0 Hz, 1H), 2.38 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 144.0, 137.1, 135.5, 133.6, 132.6, 129.7, 129.6, 128.7, 128.5, 128.5, 127.6, 126.9, 124.2, 121.2, 79.0, 77.7, 72.9, 71.3, 48.0, 21.6; MS (ESI) found: 434.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₆H₂₁NNaO₂S [M+Na]⁺ 434.1191, found: 434.1194; IR (neat) ν 3444, 3256, 3047, 3030, 2957, 2923, 2853, 2243, 1336, 1157, 750, 690, 673, 573 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) *t*_R (minor) = 18.2 min, *t*_R (major) = 31.1 min.




N-(1,5-diphenylpenta-2,4-diyn-1-yl)cyclopropanesulfonamide (3pa) : 30.2 mg, 93% yield, 90% ee; mp 121–122 °C; $[\alpha]_D^{20} +42.0$ (c 1.0, CH₂Cl₂); ¹H-NMR (400 MHz, CDCl₃) δ 7.58 (d, *J* = 7.2 Hz, 2H), 7.51 (d, *J* = 7.2 Hz, 2H), 7.44 – 7.30 (m, 6H), 5.55 (d, *J* = 8.9 Hz, 1H), 4.95 (d, *J* = 8.9 Hz, 1H), 2.61 – 2.51 (m, 1H), 1.36 – 1.28 (m, 1H), 1.16 – 1.10 (m, 1H), 1.05 – 0.96 (m, 1H), 0.92 – 0.80 (m, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ 137.0, 132.7, 129.6, 129.0, 128.8, 128.5, 127.3, 121.1, 79.8, 79.3, 73.0, 71.3, 50.0, 31.5, 6.6, 5.8; HR-MS (APCI) calcd for C₂₀H₁₈NO₂S [M+H]⁺ 336.1052, found: 336.1047; IR (neat) ν 3290, 3251, 3081, 3062, 3032, 2927, 2866, 2243, 1599, 1490, 1441, 1332, 1146, 1042, 755, 719, 698, 685, 578 cm⁻¹; HPLC

(DAICEL Chiralpak IC, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 254 nm) t_R (major) = 9.9 min, t_R (minor) = 11.0 min.



***N*-(1,5-diphenylpenta-2,4-diyn-1-yl)-1-allylcyclopropane-1-sulfonamide (3qa) :**


34.1 mg, 91% yield, 90% ee; mp 109 – 111 °C; $[\alpha]_D^{20}$ +40.6 (*c* 1.0, CH₂Cl₂); ¹H-NMR (400 MHz, CDCl₃) δ 7.57 (d, *J* = 7.3 Hz, 2H), 7.52 (d, *J* = 7.2 Hz, 2H), 7.42 – 7.31 (m, 6H), 5.89 – 5.74 (m, 1H), 5.50 (d, *J* = 8.8 Hz, 1H), 5.24 – 5.10 (m, 2H), 4.88 (d, *J* = 8.8 Hz, 1H), 2.82 (dd, *J* = 14.4, 7.9 Hz, 1H), 2.68 (dd, *J* = 14.4, 6.7 Hz, 1H), 1.54 – 1.45 (m, 1H), 1.43 – 1.33 (m, 1H), 1.08 – 0.99 (m, 1H), 0.88 – 0.81 (m, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ 137.3, 133.1, 132.67, 129.6, 129.0, 128.8, 128.5, 127.3, 121.1, 119.3, 79.9, 79.3, 73.0, 71.3, 50.1, 39.6, 34.9, 11.1, 9.8; HR-MS (APCI) calcd for C₂₃H₂₂NO₂S [M+H]⁺ 376.1365, found: 376.1358; IR (neat) ν 3255, 3065, 3032, 3015, 2975, 2922, 2854, 2243, 1489, 1449, 1416, 1317, 1131, 1023, 925, 757, 694, 632, 564 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) t_R (minor) = 6.4 min, t_R (major) = 11.7 min.




***N*-(1,1,1-trifluoro-6-phenylhexa-3,5-diyn-2-yl)-4-methylbenzenesulfonamide**

(3ra): 27.9 mg, 74% yield, 61% ee (**L10** was used as the chiral ligand); mp 156–157 °C; $[\alpha]_D^{20}$ +55.6 (*c* 1.0, CH₂Cl₂); ¹H-NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 7.9 Hz, 2H), 7.46 (d, *J* = 7.3 Hz, 2H), 7.42 – 7.30 (m, 5H), 5.53 – 5.37 (m, 1H), 4.86 (s, 1H), 2.42 (s, 3H); ¹³C-NMR (100 MHz, CDCl₃) δ 144.6, 136.5, 132.7, 130.0, 129.9, 128.6, 127.3, 122.1 (q, ¹*J*_{F-C} = 280.0 Hz), 120.4, 79.8, 72.1, 72.0, 70.9, 49.2 (q, ²*J*_{F-C} = 36.9

Hz), 21.6; ^{19}F -NMR (376 MHz, CDCl_3) δ -75.24 (d, J = 6.0 Hz); HR-MS (ESI) calcd for $\text{C}_{19}\text{H}_{15}\text{F}_3\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$ 378.0770, found: 378.0776; IR (neat) ν 3274, 3047, 2931, 2877, 2247, 1595, 1447, 1345, 1268, 1191, 1154, 1084, 921, 689 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 4.7 min, t_R (major) = 6.5 min.




(S)-4-methyl-N-(8-phenylocta-5,7-diyn-4-yl)benzenesulfonamide (3sa) : 26.0 mg, 74% yield, 63% ee (**L10** was used as the chiral ligand); mp 118 – 120 °C; $[\alpha]_D^{20}$ +99.4 (*c* 1.0, CH_2Cl_2); ^1H -NMR (400 MHz, CDCl_3) δ 7.81 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 7.0 Hz, 2H), 7.39 – 7.28 (m, 5H), 4.89 (d, J = 9.4 Hz, 1H), 4.26 – 4.13 (m, 1H), 2.38 (s, 3H), 1.72 – 1.66 (m, 2H), 1.52 – 1.41 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 143.8, 137.1, 132.5, 129.7, 129.4, 128.5, 127.5, 121.3, 80.5, 78.1, 73.0, 69.1, 46.2, 38.3, 21.6, 18.7, 13.4; HR-MS (ESI) calcd for $\text{C}_{21}\text{H}_{25}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{NH}_4]^+$ 369.1637, found: 369.1638; IR (neat) ν 3450, 3269, 2960, 2934, 2873, 2240, 1598, 1332, 1158, 1090, 1022, 880, 760, 692, 666, 572, 535 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 5.6 min, t_R (major) = 6.2 min.




N-(5-(4-fluorophenyl)-1-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ab) : 37.1 mg, 92% yield, 90% ee; mp 139–140 °C; $[\alpha]_D^{20}$ +92.4 (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.80 (d, J = 8.2 Hz, 2H), 7.48 – 7.41 (m, 4H), 7.38 – 7.30 (m, 5H), 7.03 (t, J = 8.6 Hz, 2H), 5.45 (d, J = 9.0 Hz, 1H), 5.06 (d, J = 9.0 Hz, 1H), 2.39 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 163.2 (d, $^1J_{\text{F-C}}$ = 250.8 Hz), 143.8,

137.1, 136.5, 134.6 (d, $^3J_{F-C} = 8.6$ Hz), 129.7, 128.9, 128.7, 127.5, 127.2, 117.3 (d, $^4J_{F-C} = 3.5$ Hz), 116.0 (d, $^2J_{F-C} = 22.3$ Hz), 78.6, 77.8, 72.7, 71.1, 49.9, 21.6; ^{19}F -NMR (376 MHz, CDCl_3) δ -107.91 – -107.99 (m, 1F); MS (ESI) found: 426.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{FNNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 426.0940, found: 426.0942; IR (neat) ν 3418, 3263, 3067, 3033, 2924, 2852, 2243, 1598, 1505, 1335, 1233, 1156, 1091, 834, 677, 573, 544 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_R (minor) = 6.8 min, t_R (major) = 7.0 min.




***N*-(5-(4-chlorophenyl)-1-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ac)**: 39.0 mg, 95% yield, 95% ee; mp 114–118 °C; $[\alpha]_D^{20} +74.0$ (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.80 (d, $J = 8.2$ Hz, 2H), 7.45 (d, $J = 6.1$ Hz, 2H), 7.38 (d, $J = 8.6$ Hz, 2H), 7.35 – 7.29 (m, 7H), 5.45 (d, $J = 8.9$ Hz, 1H), 4.96 (d, $J = 8.9$ Hz, 1H), 2.40 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 143.9, 137.0, 136.4, 135.8, 133.7, 129.7, 128.9, 128.9, 128.8, 127.5, 127.2, 119.7, 79.2, 77.7, 73.9, 71.0, 49.9, 21.6; MS (ESI) found: 442.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{ClNNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 442.0644, found: 442.0635; IR (neat) ν 3405, 3258, 3061, 3032, 2922, 2854, 2245, 1597, 1490, 1336, 1160, 1090, 827, 670, 579 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) t_R (minor) = 7.1 min, t_R (major) = 8.0 min.




(*S*)-*N*-(5-(4-bromophenyl)-1-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ad): 45.0 mg, 97% yield, 90% ee (>99.9 after recrystallization); mp 83–87 °C; $[\alpha]_D^{20} +71.2$ (*c* 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.80 (d, $J = 8.1$ Hz, 2H),

7.50 – 7.42 (m, 4H), 7.37 – 7.28 (m, 7H), 5.45 (d, $J = 8.9$ Hz, 1H), 5.05 (d, $J = 9.0$ Hz, 1H), 2.39 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 143.9, 137.0, 136.4, 133.8, 131.9, 129.7, 128.9, 128.8, 127.5, 127.2, 124.1, 120.1, 79.3, 77.8, 74.0, 71.0, 49.9, 21.6; MS (ESI) found: 486.0 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{18}\text{BrNNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 486.0139, found: 486.0138; IR (neat) ν 3361, 3255, 3065, 2961, 2921, 2857, 2243, 1601, 1570, 1321, 1157, 1089, 814, 784, 672, 544 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) t_{R} (minor) = 7.3 min, t_{R} (major) = 8.2 min.




***N*-(1-phenyl-5-(*p*-tolyl)penta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ae):** 37.9 mg, 95% yield, 93% ee; mp 154–156 °C; $[\alpha]_{\text{D}}^{20} +91.4$ (c 1.0, CH_2Cl_2); ^1H -NMR (CDCl_3 , 400 MHz) δ 7.81 (d, $J = 8.1$ Hz, 2H), 7.46 (d, $J = 6.4$ Hz, 2H), 7.37 – 7.29 (m, 7H), 7.14 (d, $J = 7.8$ Hz, 2H), 5.45 (d, $J = 9.1$ Hz, 1H), 5.15 (d, $J = 9.1$ Hz, 1H), 2.39 (s, 3H), 2.36 (s, 3H); ^{13}C -NMR (CDCl_3 , 100 MHz) δ 143.9, 140.0, 137.0, 136.7, 132.5, 129.7, 129.3, 128.8, 128.7, 127.5, 127.3, 118.1, 79.3, 78.2, 72.4, 71.5, 50.0, 21.6; MS (ESI) found: 442.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{25}\text{H}_{21}\text{NNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 422.1191, found: 422.1183; IR (neat) ν 3426, 3261, 3062, 3033, 2918, 2854, 2238, 1600, 1334, 1159, 1091, 1030, 810, 673, 633, 572, 544 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.8 mL / min, 220 nm) t_{R} (minor) = 8.9 min, t_{R} (major) = 12.2 min.




***N*-(5-(4-methoxyphenyl)-1-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3af):** 40.6 mg, 98% yield, 97% ee; mp 153–155 °C; $[\alpha]_{\text{D}}^{20} +107.4$ (c 1.0, CH_2Cl_2);

$^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.79 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 6.6 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.35 – 7.29 (m, 5H), 6.84 (d, J = 8.7 Hz, 2H), 5.45 (d, J = 9.0 Hz, 1H), 5.12 (s, 1H), 3.81 (s, 3H), 2.39 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3 , 100 MHz) δ 160.6, 143.8, 137.1, 136.7, 134.2, 129.7, 128.8, 128.7, 127.5, 127.3, 114.2, 113.1, 79.2, 78.0, 71.8, 71.6, 55.4, 50.0, 21.6; MS (ESI) found: 438.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{25}\text{H}_{21}\text{NNaO}_3\text{S}$ $[\text{M}+\text{Na}]^+$ 438.1140, found: 438.1134; IR (neat) ν 3451, 3262, 2965, 2932, 2837, 2239, 1602, 1508, 1430, 1335, 1254, 1157, 1029, 830, 681, 543 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.8 mL / min, 220 nm) t_{R} (minor) = 12.7 min, t_{R} (major) = 32.1 min.




***N*-(5-(2-methoxyphenyl)-1-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3ag)** : 37.4 mg, 90% yield, 93% ee; mp 153–154 °C; $[\alpha]_{\text{D}}^{20}$ +92.0 (c 1.0, CH_2Cl_2); $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.80 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 6.4 Hz, 2H), 7.40 (d, J = 7.5 Hz, 1H), 7.38 – 7.28 (m, 6H), 6.90 (dd, J = 15.9, 8.1 Hz, 2H), 5.46 (d, J = 9.0 Hz, 1H), 5.01 (s, 1H), 3.88 (s, 3H), 2.39 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3 , 100 MHz) δ 161.5, 143.9, 137.0, 136.7, 134.5, 131.0, 129.7, 128.8, 128.7, 127.5, 127.3, 120.6, 110.8, 110.4, 79.0, 76.6, 75.6, 71.6, 55.8, 50.0, 21.6; MS (ESI) found: 438.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{25}\text{H}_{21}\text{NNaO}_3\text{S}$ $[\text{M}+\text{Na}]^+$ 438.1140, found: 438.1118; IR (neat) ν 3450, 3261, 3007, 2920, 2850, 2238, 1594, 1491, 1330, 1277, 1158, 1024, 750, 701, 570, 545 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 50 / 50, 0.6 mL / min, 220 nm) t_{R} (minor) = 13.0 min, t_{R} (major) = 35.7 min.




***N*-(5-(2-chlorophenyl)-1-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide**


e (3ah) : 37.0 mg, 88% yield, 90% ee; mp 163–165 °C; $[\alpha]_D^{20} +75.4$ (c 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.81 (d, *J* = 8.2 Hz, 2H), 7.47 (m, 3H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.37 – 7.27 (m, 6H), 7.22 (t, *J* = 7.6 Hz, 1H), 5.48 (d, *J* = 9.1 Hz, 1H), 5.08 (d, *J* = 9.1 Hz, 1H), 2.38 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 144.0, 136.9, 136.9, 136.4, 134.3, 130.4, 129.7, 129.5, 128.9, 128.8, 127.5, 127.3, 126.6, 121.4, 80.1, 77.6, 75.3, 71.0, 50.0, 21.6; MS (ESI) found: 442.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₄H₁₈ClNNaO₂S [M+Na]⁺ 442.0644, found: 442.0635; IR (neat) ν 3425, 3277, 3063, 3032, 2856, 2243, 1588, 1434, 1333, 1157, 1081, 1040, 759, 672, 572, 546 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) *t*_R (minor) = 7.1 min, *t*_R (major) = 9.6 min.




N-(5-(3-methoxyphenyl)-1-phenylpenta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3ai) : 38.6 mg, 93% yield, 88% ee; mp 160–162 °C; $[\alpha]_D^{20} +83.8$ (c 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.81 (d, *J* = 8.2 Hz, 2H), 7.46 (d, *J* = 6.3 Hz, 2H), 7.38 – 7.29 (m, 5H), 7.23 (d, *J* = 7.9 Hz, 1H), 7.05 (d, *J* = 7.6 Hz, 1H), 6.94 (dd, *J* = 12.6, 4.3 Hz, 2H), 5.46 (d, *J* = 9.0 Hz, 1H), 4.95 (d, *J* = 9.0 Hz, 1H), 3.80 (s, 3H), 2.41 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 159.3, 143.9, 137.0, 136.5, 129.7, 129.6, 128.9, 128.8, 127.5, 127.3, 125.1, 122.1, 117.3, 116.1, 78.9, 78.5, 72.6, 71.3, 55.3, 50.0, 21.6; MS (ESI) found: 438.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₅H₂₁NNaO₃S [M+Na]⁺ 438.1140, found: 438.1130; IR (neat) ν 3429, 3286, 3004, 2961, 2924, 2836, 2237, 1600, 1573, 1427, 1331, 1314, 1161, 1041, 677, 572, 547 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 1.0 mL / min, 220 nm) *t*_R (minor) = 8.9 min, *t*_R (major) = 17.8 min.




***N*-(5-(cyclohex-1-en-1-yl)-1-phenylpenta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3aj)** : 37.8 mg, 97% yield, 95% ee; mp 132–134 °C; $[\alpha]_D^{20} +89.2$ (c 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.76 (d, *J* = 8.2 Hz, 2H), 7.42 (d, *J* = 6.2 Hz, 2H), 7.34 – 7.26 (m, 5H), 6.25 (s, 1H), 5.40 (d, *J* = 9.0 Hz, 1H), 5.02 (t, *J* = 8.3 Hz, 1H), 2.42 (s, 3H), 2.14 – 2.05 (m, 4H), 1.64 – 1.54 (m, 4H); ¹³C-NMR (CDCl₃, 100 MHz) δ 143.7, 139.5, 137.0, 136.8, 129.6, 128.8, 128.6, 127.5, 127.3, 119.4, 81.1, 77.5, 71.6, 70.5, 50.0, 28.6, 25.9, 22.0, 21.6, 21.2; MS (ESI) found: 412.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₄H₂₃NNaO₂S [M+Na]⁺ 412.1347, found: 412.1349; IR (neat) ν 3448, 3260, 3033, 2931, 2858, 2233, 1598, 1335, 1158, 1089, 810, 674, 542 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 90 / 10, 1.0 mL / min, 220 nm) *t*_R (minor) = 12.6 min, *t*_R (major) = 13.8 min.



***N*-(1-phenyl-5-(triisopropylsilyl)penta-2,4-diyn-1-yl)-4-methylbenzenesulfonamide (3ak)**: 44.4 mg, 95% yield, 93% ee; mp 67–69 °C; $[\alpha]_D^{20} +1.3$ (c 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.78 (d, *J* = 8.2 Hz, 2H), 7.43 (d, *J* = 6.2 Hz, 2H), 7.35 – 7.26 (m, 5H), 5.40 (d, *J* = 8.9 Hz, 1H), 5.17 (d, *J* = 8.9 Hz, 1H), 2.42 (s, 3H), 1.08 (s, 21H); ¹³C-NMR (CDCl₃, 100 MHz) δ 143.7, 137.0, 136.6, 129.6, 128.8, 128.7, 127.5, 127.3, 88.5, 85.2, 72.7, 71.7, 49.7, 21.6, 18.5, 11.2; MS (ESI) found: 488.2 [M+Na]⁺; HR-MS (ESI) calcd for C₂₇H₃₅NNaO₂SSi [M+Na]⁺ 488.2055, found: 488.2064; IR (neat) ν 3360, 3261, 3063, 2943, 2865, 2352, 1592, 1156, 1090, 883, 824, 665, 553 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 90 / 10, 0.8 mL / min, 220 nm) *t*_R (major) = 8.4 min, *t*_R (minor) = 9.0 min.




***N*-(6-methyl-1-phenyl-6-((trimethylsilyl)oxy)hepta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3al)** : 39.6 mg, 90% yield, 92% ee; $[\alpha]_{\text{D}}^{20} +68.4$ (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.77 (d, *J* = 8.1 Hz, 2H), 7.42 (d, *J* = 6.2 Hz, 2H), 7.35 – 7.28 (m, 5H), 5.40 (d, *J* = 8.9 Hz, 1H), 5.02 (d, *J* = 8.9 Hz, 1H), 2.44 (s, 3H), 1.47 (s, 6H), 0.17 (s, 9H); ¹³C-NMR (CDCl₃, 100 MHz) δ 143.7, 137.1, 136.6, 129.6, 128.8, 128.7, 127.5, 127.2, 84.7, 75.6, 70.6, 66.9, 66.8, 49.7, 32.6, 21.7, 1.8; MS (ESI) found: 462.2 [M+Na]⁺; HR-MS (ESI) calcd for C₂₄H₂₉NNaO₃SSi [M+Na]⁺ 462.1535, found: 462.1538; IR (neat) ν 3417, 3264, 3064, 3033, 2984, 2961, 2932, 2352, 1598, 1453, 1333, 1250, 1163, 1034, 842 cm⁻¹; HPLC (DAICEL Chiralpak IA, Hexane / *i*-PrOH = 98.7 / 1.3, 1.0 mL / min, 220 nm) *t*_R (minor) = 26.7 min, *t*_R (major) = 33.7 min.




***N*-(1,7-diphenylhepta-2,4-diyne-1-yl)-4-methylbenzenesulfonamide (3am)** : 38.8 mg, 94% yield, >99% ee; mp 105–107 °C; $[\alpha]_{\text{D}}^{20} +58.6$ (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.76 (d, *J* = 8.1 Hz, 2H), 7.43 (d, *J* = 6.0 Hz, 2H), 7.35 – 7.25 (m, 8H), 7.20 (d, *J* = 7.3 Hz, 2H), 5.36 (d, *J* = 8.9 Hz, 1H), 4.96 (d, *J* = 8.9 Hz, 1H), 2.83 (t, *J* = 7.5 Hz, 2H), 2.55 (t, *J* = 7.5 Hz, 2H), 2.40 (s, 3H); ¹³C-NMR (CDCl₃, 100 MHz) δ 143.7, 139.9, 137.0, 136.8, 129.6, 128.8, 128.6, 128.6, 128.4, 127.5, 127.3, 126.6, 81.1, 72.0, 71.6, 64.9, 49.7, 34.5, 21.6, 21.5; MS (ESI) found: 436.1 [M+Na]⁺; HR-MS (ESI) calcd for C₂₆H₂₃NNaO₂S [M+Na]⁺ 436.1347, found: 436.1348; IR (neat) ν 3426, 3272, 3059, 3030, 2924, 2856, 2255, 1329, 1156, 1051, 698, 663, 543 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) *t*_R (minor) = 9.2 min, *t*_R (major) = 10.0 min.


4. Further transformation of adduct **3aa**.




A solution of compound **3aa** (38.5 mg, 0.1 mmol, 94% ee) in abs EtOH (10 mL) was stirred under hydrogen (balloon) in the presence of 10% Pd/C (10 mg) for 1.5 h. After this time, the mixture was filtered through a short pad of silica gel, eluting with EtOAc, and the solvent was removed under reduced pressure to give compound **4** (39 mg, 94% ee).




N-(1,5-diphenylpentyl)-4-methylbenzenesulfonamide (4) : 39 mg, 99% yield, 94% ee; $[\alpha]_{\text{D}}^{20}$ -21.0 (*c* 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.58 (d, *J* = 8.1 Hz, 2H), 7.27 (t, *J* = 7.4 Hz, 2H), 7.19 (d, *J* = 7.2 Hz, 1H), 7.17 – 7.13 (m, 3H), 7.11 (d, *J* = 7.8 Hz, 4H), 7.04 (m, 2H), 5.57 (d, *J* = 6.0 Hz, 1H), 4.27 (q, *J* = 7.3 Hz, 1H), 2.55 – 2.46 (m, 2H), 2.35 (s, 3H), 1.86 – 1.77 (m, 1H), 1.76 – 1.67 (m, 1H), 1.60 – 1.47 (m, 2H), 1.34 – 1.26 (m, 1H), 1.2 – 1.14 (m, 1H); ¹³C-NMR (CDCl₃, 100 MHz) δ 142.9, 142.4, 141.1, 137.8, 129.3, 128.4, 128.4, 128.3, 127.2, 127.1, 126.6, 125.7, 58.3, 37.5, 35.6, 30.9, 25.6, 21.5; MS (ESI) found: 416.2 [M+Na]⁺; HR-MS (ESI) calcd for C₂₄H₂₇NNaO₂S [M+Na]⁺ 416.1660, found: 416.1648; IR (neat) ν 3275, 3061, 3028, 2931, 2857, 1600, 1453, 1324, 1158, 1091, 701, 668, 556 cm⁻¹; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 70 / 30, 0.9 mL / min, 220 nm) *t*_R (minor) = 7.1 min, *t*_R (major) = 10.3 min.




Hydrogenation adduct **4** (39.4 mg, 0.1 mmol, 94% ee) in dry THF (2 mL) was added to a 0.1 M THF solution of SmI₂ (12 mL, 1.2 mmol) and HMPA (1 mL) at rt under nitrogen. The solution was heated at 70 °C for 2h until the purple color of the solution disappeared. The reaction was cooled at rt and quenched with satd aqueous NaCl and extracted with diethyl ether. The organic layer was washed with brine (several times), dried over Na₂SO₄ and concentrated under reduced pressure. Purification by chromatography (Petroleum ether-EtOAc 1:1, containing 10 drops Et₃N for 100 ml of eluent) on silica gel afforded compound **5** (16.3 mg).



(R)-1,5-diphenylpentan-1-amine (5) : 16.3 mg, 68% yield, 94% ee; $[\alpha]_D^{20}$ -7.6 (c 1.0, CH₂Cl₂); ¹H-NMR (CDCl₃, 400 MHz) δ 7.36 – 7.28 (m, 4H), 7.24 (s, 2H), 7.20 – 7.10 (m, 3H), 3.87 (t, *J* = 6.9 Hz, 1H), 2.63 – 2.50 (m, 2H), 2.03 (br s, 2H), 1.77 – 1.67 (m, 2H), 1.66 – 1.57 (m, 2H), 1.49 – 1.28 (m, 2H); ¹³C-NMR (101 MHz, CDCl₃) δ 146.6, 142.6, 128.5, 128.4, 128.3, 126.9, 126.3, 125.6, 56.2, 39.4, 35.8, 31.4, 26.3; HR-MS (ESI) calcd for C₁₇H₂₂N [M+H]⁺ 240.1752, found: 240.1752; IR ν 3436, 3061, 3027, 2958, 2929, 2856, 1602, 1454, 1283, 1265, 1123, 1074, 1026, 798, 746, 700 cm⁻¹. Determination of the ee: Tosyl chloride (18 mg, 0.086 mmol) was added to a solution of compound **5** (16.0 mg, 0.068 mmol) and pyridine (10 drops) in CH₂Cl₂ (2 mL) at rt. After 48, the mixture was diluted with EtOAc, washed with 2M HCl and brine, and dried over Na₂SO₄. The solvent was removed under reduced pressure and the residue chromatographed on silica gel to give the corresponding tosyl imine **4** (20.0 mg, 0.051 mmol, 75%) which was analyzed by HPLC as described above (94% ee).



To a -78°C solution of **3aa** (38.5 mg, 0.1 mmol, 94% ee) in anhydrous THF (1 ml) containing 1,2-dichlorobenzene (29.4 mg, 0.2 mmol) was dropwise via an addition funnel a 1M solution in THF of LiAlH_4 . Followed the solution of LiAlH_4 the cooling bath was removed and the mixture was stirred at room temperature overnight. Upon completion of the reaction, the mixture was cooled to 0°C , and carefully quenched with 20% KHSO_4 , filtrated and extracted with EtOAc ($3 \times 10\text{mL}$) washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. Purification by flash chromatography on silica gel afforded compound **6** (32.5 mg, 94% ee).







(E)-N-(1,5-diphenylpent-2-en-4-yn-1-yl)-4-methylbenzenesulfonamide (6) : 32.5 mg, 85% yield, 94% ee; mp $164\text{--}166^\circ\text{C}$; $[\alpha]_{\text{D}}^{20} +20.8$ (c 1.0, CH_2Cl_2); $^1\text{H-NMR}$ (CDCl_3 , 400 MHz) δ 7.66 (d, $J = 8.1$ Hz, 2H), 7.41 – 7.35 (m, 2H), 7.32 – 7.27 (m, 3H), 7.26 – 7.20 (m, 5H), 7.16 – 7.08 (m, 2H), 6.15 (dd, $J = 15.8, 6.2$ Hz, 1H), 5.76 (d, $J = 15.8$ Hz, 1H), 5.06 – 4.99 (m, 1H), 4.96 (d, $J = 7.0$ Hz, 1H), 2.38 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3 , 100 MHz) δ 143.5, 141.1, 138.7, 137.5, 131.5, 129.6, 128.7, 128.4, 128.3, 128.2, 127.3, 127.1, 123.0, 112.5, 91.2, 86.7, 59.4, 21.5; MS (ESI) found: 410.1 $[\text{M}+\text{Na}]^+$; HR-MS (ESI) calcd for $\text{C}_{24}\text{H}_{21}\text{NNaO}_2\text{S}$ $[\text{M}+\text{Na}]^+$ 410.1191, found: 410.1201; IR (neat) ν 3427, 3327, 3244, 3061, 3029, 2961, 2924, 2868, 2353, 1597, 1432, 1325, 1165, 1091, 697, 674, 565 cm^{-1} ; HPLC (DAICEL Chiralpak IB, Hexane / *i*-PrOH = 50 / 50, 0.5 mL / min, 220 nm) t_{R} (minor) = 9.9 min, t_{R} (major) = 29.8 min.



5. References:



1. (a) T. Ooi, M. Kameda, K. J. Maruoka, *J. Am. Chem. Soc.*, 2003, **125**, 5139; (b) T. Ooi, K. J. Maruoka, *Angew. Chem., Int. Ed.*, 2007, **46**, 4222; (c) T. Hashimoto, K. J. Maruoka, *Chem. Rev.*, 2007, **107**, 5656.
2. For the synthesis of substituted terminal 1,3-Diynes see: (a) X.-W. Jiang, M. Rawat, W. D. Wulff, *J. Am. Chem. Soc.*, 2004, **126**, 5970. For the synthesis of substituted *N*-sulfonyl aldimines see: (a) J. Esquivias, R. Gómez Arrayás, J. C. Carretero, *Angew. Chem., Int. Ed.*, 2006, **45**, 629; (b) Z. Cui, H.-J. Yu, R.-F. Yang, W.-Y. Gao, C.-G. Feng, G.-Q. Lin, *J. Am. Chem. Soc.*, 2011, **132**, 12394; (c) S. Jonoshita, A. Harada, M. Omote, A. Ando, I. Kumadaki, *J. Fluorine. Chem.*, 1999, **97**, 61.



6. NMR Spectra and HPLC Charts for the Addition Adducts












































































































































Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 1.0 mL/min




Sample Info : 220nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min



Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min





Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %	Height [mAU]
1	9.185	VV	0.2492	1.56115e4	50.5887	946.68933
2	23.095	BB	0.6797	1.52482e4	49.4113	341.45227





Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %	Height [mAU]
1	9.241	BB	0.2584	104.76035	0.8660	6.14977
2	24.141	BB	0.7086	1.19917e4	99.1340	257.16379



Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min





Sample Info : 220nm, IB, i-PrOH : Hexane =30:70, 0.8 mL/min





Sample Info : 220nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min



Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min



Signal 1: VWD1 A, Wavelength=220 nm



Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	5.562	VV	0.1265	1.78083e4	2166.47363	49.4045
2	9.177	BB	0.2318	1.82377e4	1195.80127	50.5955





Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	5.573	VV	0.1463	418.59106	41.68880	3.6801
2	9.185	VB	0.2297	1.09557e4	726.86371	96.3199



Sample Info : 220nm, IB, i-PrOH : Hexane =30:70, 0.8 mL/min
VWD1 A, Wavelength=220 nm (LTL-INTES1000246.D)





Sample Info : 220 nm, IB, i-PrOH : Hexane =50:50, 0.6 mL/min





Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min





Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min





Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min




Sample Info : 254 nm, IC, i-PrOH : Hexane =30:70, 0.9mL/min



Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min





Signal 1: VWD1 A, Wavelength=220 nm

Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	4.830	VV	0.1977	1.14750e4	837.63593	50.2303
2	6.771	VB	0.2622	1.13698e4	632.27618	49.7697





Peak #	RetTime [min]	Type	Width [min]	Area mAU *s	Height [mAU]	Area %
1	4.732	BV	0.1674	1457.63159	128.42072	19.5542
2	6.467	BB	0.2448	5996.66406	358.27545	80.4458

Sample Info : 220nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min

VWD1 A, Wavelength=220 nm (LTL-INTES1000251.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	7.059	BV	0.2165	3548.16113		247.86551	49.4413
2	8.148	VB	0.2653	3628.35303		205.88063	50.5587





Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	7.063	BV	0.1993	508.44122		38.46938	2.5066
2	8.023	VB	0.2272	1.97759e4		1319.88562	97.4934

Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 1.0 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.8 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.8mL/min

VWD1 A, Wavelength=220 nm (LTL-INTES 1000279.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %	Height [mAU]
1	12.754	VV	0.3783	1809.28320	50.2933	71.82845
2	32.747	VB	0.9936	1788.18359	49.7067	26.81247

VWD1 A, Wavelength=220 nm (LTL-INTES 1000280.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	Area %	Height [mAU]
1	12.724	BB	0.3814	239.14543	1.6830	9.63257
2	32.076	BBA	0.9937	1.39700e4	98.3170	209.82607

Sample Info : 220 nm, IB, i-PrOH : Hexane = 50:50, 0.6 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane = 30:70, 1.0 mL/min




Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 1.0 mL/min

VWD1_A, Wavelength=220 nm (LTL-INTES1000148.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	8.752	BB	0.2434	2831.19507		175.66168	50.2209
2	17.036	BB	0.5050	2806.29248		84.57775	49.7791

VWD1_A, Wavelength=220 nm (LTL-INTES1000178.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	8.923	VB	0.2497	639.71649		38.98952	5.9819
2	17.784	BB	0.5334	1.00544e4		285.34174	94.0181

Sample Info : 220 nm, IB, i-PrOH : Hexane =10:90, 1.0 mL/min




Sample Info : 220nm, IB, i-PrOH : Hexane =10:90, 0.8 mL/min




Sample Info : 220nm, IA, i-PrOH : Hexane =1.3:98.7, 1.0 mL/min

\\VVD1.A\Wavelength=220 nm (LTL-INTES 1000262.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	27.215	BB	0.7470	2323.74902		46.65929	49.2908
2	34.638	BB	0.9037	2390.62109		39.93598	50.7092

\\VVD1.A\Wavelength=220 nm (LTL-INTES 1000263.D)





Peak #	RetTime [min]	Type	Width [min]	Area mAU	*s	Height [mAU]	Area %
1	26.680	BB	0.6652	213.72380		4.47277	4.1499
2	33.713	BB	0.8625	4936.40234		86.48101	95.8501



Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min



Sample Info : 220 nm, IB, i-PrOH : Hexane =30:70, 0.9 mL/min



Sample Info : 220 nm, IB, i-PrOH : Hexane =50:50, 0.5 mL/min



7. X-Ray Analysis for the Adduct **3ad:**

CCDC 870991 contains the supplementary crystallographic data for the adduct **3ad**.

These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.